Last reviewed · How we verify
MMF/EC-MPS
MMF/EC-MPS is an inosine monophosphate dehydrogenase (IMPDH) inhibitor that selectively suppresses T and B lymphocyte proliferation to prevent organ rejection.
MMF/EC-MPS is an inosine monophosphate dehydrogenase (IMPDH) inhibitor that selectively suppresses T and B lymphocyte proliferation to prevent organ rejection. Used for Prevention of organ rejection in renal transplant recipients, Prevention of organ rejection in cardiac transplant recipients, Prevention of organ rejection in hepatic transplant recipients.
At a glance
| Generic name | MMF/EC-MPS |
|---|---|
| Also known as | MPA, Myfortic, Cellcept |
| Sponsor | Novartis |
| Drug class | Immunosuppressant; IMPDH inhibitor |
| Target | Inosine monophosphate dehydrogenase (IMPDH) type II |
| Modality | Small molecule |
| Therapeutic area | Immunology; Transplantation |
| Phase | FDA-approved |
Mechanism of action
Mycophenolate mofetil (MMF) and its active metabolite mycophenolic acid (MPA) inhibit IMPDH type II, an enzyme critical for guanosine nucleotide synthesis in lymphocytes. By depleting guanosine nucleotides, the drug preferentially blocks T and B cell proliferation while sparing other cell types, thereby reducing immune-mediated rejection of transplanted organs. EC-MPS (enteric-coated mycophenolate sodium) is a formulation designed to improve gastrointestinal tolerability.
Approved indications
- Prevention of organ rejection in renal transplant recipients
- Prevention of organ rejection in cardiac transplant recipients
- Prevention of organ rejection in hepatic transplant recipients
Common side effects
- Diarrhea
- Nausea
- Vomiting
- Abdominal pain
- Leukopenia
- Anemia
- Infection
- Tremor
Key clinical trials
- Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients (PHASE2)
- Tacrolimus and Personalized Therapy to Prevent Acute Rejection Episodes
- Induction in Sensitized Kidney Transplant Recipients Without Pre-existing Donor-specific antiboDies (PHASE3)
- Efficacy and Safety of Enteric-Coated Mycophenolate Sodium (EC-MPS) in de Novo Kidney Transplant Recipients (PHASE4)
- Measurement of Patient Reported Gastrointestinal (GI) and Health-related Quality of Life (HRQL) Outcomes in Renal Transplant Recipients (MyLife) (PHASE4)
- Influence of Pantoprazole on the Bioavailability of MMF and EC-MPS (PHASE4)
- A Study Investigating the Renal Tolerability, Efficacy, and Safety of a CNI-free Versus a Standard Regimen in de Novo Heart Transplant (HTx) Recipients (PHASE4)
- A Gastrointestinal Quality of Life Study in Lung Transplant Recipients Converted From Mycophenolate Mofetil to Myfortic (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MMF/EC-MPS CI brief — competitive landscape report
- MMF/EC-MPS updates RSS · CI watch RSS
- Novartis portfolio CI